Complete response after two cycles of enfortumab vedotin in a patient with metastatic bladder cancer: A case report

Abstract

Metastatic urothelial carcinoma, the most common subtype of advanced bladder cancer, remains associated with poor outcomes and limited treatment options despite systemic therapies. Enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has shown significant improvements in progression-free and overall survival in platinum- and immunotherapy-pretreated patients, as demonstrated in the EV-201 and EV-301 trials. In this report, we present a case of a patient who had previously received platinum-based neoadjuvant chemotherapy and experienced disease progression under nivolumab maintenance therapy but subsequently achieved a complete response in a short period with EV treatment. EV has emerged as a valuable treatment alternative in this aggressive disease, where survival expectations are generally poor. However, questions remain regarding which patients benefit most from the treatment and whether the response is correlated with nectin-4 expression levels.

Keywords

Metastatic urothelial carcinoma / Enfortumab vedotin / Complete response

References

[1] Gore JL, Wright P, Shih V, et al. Development and optimization of a bladder cancer algorithm using SEER-Medicare claims data. JCO Clin Cancer Inform. 2024;8:e2400073. doi: 10.1200/CCI.24.00073

[2] Reddy AC, Gu JZ, Koo BH, Fruh V, Sax AJ. Urothelial carcinoma: Epidemiology and imaging-based review. R I Med J (2013). 2024; 107(5):26-32.

[3] Lenis AT, Lec PM, Chamie K, Mshs MD.Bladder cancer: A review. JAMA. 2020; 324(19):1980-1991. doi: 10.1001/jama.2020.17598

[4] Dobruch J, Oszczudłowski M. Bladder cancer: Current challenges and future directions. Med (Kaunas). 2021; 57(8):749. doi: 10.3390/medicina57080749

[5] Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016; 76(10):3003-3013. doi: 10.1158/0008-5472.CAN-15-1313

[6] Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin- ineligible patients with advanced urothelial carcinoma (EV 201): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021; 22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2

[7] Rosenberg JE, Powles T, Sonpavde GP, et al. EV-301 long- term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023; 34(11):1047-1054. doi: 10.1016/j.annonc.2023.08.016

[8] Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet. 2017; 389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2

[9] Vuky J, Balar AV, Castellano D, et al. Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2020; 38(23):2658-2666. doi: 10.1200/JCO.19.01213

[10] Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up. Ann Oncol. 2019; 30(6):970-976. doi: 10.1093/annonc/mdz127

[11] Sharma P, Retz M, Siefher-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7

[12] Grivas P, Park SH, Voog E, et al. Avelumab first-line maintenance therapy for advanced urothelial carcinoma: Comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial. Eur Urol. 2023; 84(1):95-108. doi: 10.1016/j.eururo.2023.03.030

[13] Galsky MD, Bajorin DF, Witjes JA, et al.Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized CheckMate274 trial by PD-L1 combined positive score and tumor cell score. Eur Urol. 2023; 83(5):432-440. doi: 10.1016/j.eururo.2023.01.016

[14] Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024; 390(10):875-888. doi: 10.1056/NEJMoa2312117